Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease

Area of Science:

• Cardiology
• Preventive Medicine
• Clinical Trials

Background:

• Limited evidence exists on optimal low-density lipoprotein (LDL) cholesterol targets for secondary prevention in atherosclerotic cardiovascular disease (ASCVD).
• Guideline recommendations for LDL targets in ASCVD secondary prevention require further validation through robust clinical trials.

Purpose of the Study:

• To compare the efficacy of an intensive LDL cholesterol targeting strategy ( < 55 mg/dL) versus a conventional strategy ( < 70 mg/dL) for secondary prevention in patients with ASCVD.
• To evaluate the impact of different LDL cholesterol targets on major adverse cardiovascular events over a 3-year period.

Main Methods:

• An open-label, superiority randomized trial (Ez-PAVE) conducted in South Korea.
• 3048 patients with ASCVD were randomized 1:1 to either an intensive-targeting group (LDL < 55 mg/dL) or a conventional-targeting group (LDL < 70 mg/dL).
• The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, revascularization, or unstable angina hospitalization over 3 years.

Main Results:

• The intensive-targeting group achieved a median LDL of 56 mg/dL, while the conventional group achieved 66 mg/dL.
• A primary endpoint event occurred in 6.6% of the intensive-targeting group versus 9.7% in the conventional-targeting group (HR, 0.67; P=0.002).
• No significant differences in major safety endpoints were observed between the groups, with a notably lower incidence of creatinine elevation in the intensive-targeting group.

Conclusions:

• Targeting an LDL cholesterol level below 55 mg/dL is superior to targeting below 70 mg/dL for reducing cardiovascular events in patients with ASCVD.
• The intensive LDL-lowering strategy demonstrated a significant reduction in major adverse cardiovascular events without compromising safety.
• These findings support more aggressive LDL cholesterol lowering for secondary prevention in patients with atherosclerotic cardiovascular disease.